SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells

Anastasia A. Minervina[1#], Mikhail V. Pogorelyy[1#], Allison M. Kirk[1], Jeremy Chase Crawford[1], E. Kaitlynn Allen[1], Ching-Heng Chou[1], Robert C. Mettelman[1], Kim J. Allison[2], Chun-Yang Lin[1], David C. Brice[1], Xun Zhu[3], Kasi Vegesana[4], Gang Wu[3], Sanchit Trivedi[5], Pratibha Kottapalli[5], Daniel Darnell[5], Suzanne McNeely[5], Scott R. Olsen[5], Stacey Schultz-Cherry[2], Jeremie H. Estepp[6], the SJTRC Study Team✣, Maureen A. McGargill[1], Joshua Wolf[2], Paul G. Thomas[1]

[1] Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN USA

[2] Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN USA

[3] Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN USA

[4] Information Services, St. Jude Children's Research Hospital, Memphis, TN USA

[5] Hartwell Center for Bioinformatics & Biotechnology, St. Jude Children's Research Hospital, Memphis, TN USA

[6] Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN USA

#Equal contribution

✣ Aditya Gaur, James Hoffman, Motomi Mori, Li Tang, Elaine Tuomanen, Richard Webby, Hana Hakim, Randall T. Hayden, Diego R. Hijano, Resha Bajracharya, Walid Awad, Lee-Ann Van de Velde, Brandi L. Clark, Taylor L. Wilson, Aisha Souquette, Ashley Castellaw, Ronald H. Dallas, Jason Hodges, Ashleigh Gowen, Jamie Russell-Bell, James Sparks, David E. Wittman, Thomas P. Fabrizio, Sean Cherry, Ericka Kirkpatrick Roubidoux, Valerie Cortez, Pamela Freiden, Nicholas Wohlgemuth, Kendall Whitt;

Correspondence to Joshua Wolf joshua.wolf@stjude.org and Paul Thomas paul.thomas@stjude.org

Abstract

Although mRNA vaccine efficacy against severe COVID-19 remains high, variant emergence and breakthrough infections have changed vaccine policy to include booster immunizations. However, the effect of diverse and repeated antigen exposures on SARS-CoV-2 memory T cells is poorly understood. Here, we utilize DNA-barcoded MHC-multimers combined with scRNAseq and scTCRseq to capture the *ex vivo* profile of SARS-CoV-2-responsive T cells within a cohort of individuals with one, two, or three antigen exposures, including vaccination, primary infection, and breakthrough infection. We found that the order of exposure determined the relative distribution between spike- and non-spike-specific responses, with vaccination after infection leading to further expansion of spike-specific T cells and differentiation to a CCR7-CD45RA+ effector phenotype. In contrast, individuals experiencing a breakthrough infection mount vigorous non-spike-specific responses. In-depth analysis of over 4,000 epitope-specific T cell receptor sequences demonstrates that all types of exposures elicit diverse repertoires characterized by shared, dominant TCR motifs, with no evidence for repertoire narrowing from repeated exposure. Our findings suggest that breakthrough infections diversify the T cell memory repertoire and that current vaccination protocols continue to expand and differentiate spike-specific memory responses.

The continued evolution of SARS-CoV-2 into diverse lineages has led to reduced efficacy of neutralizing antibody responses raised against ancestral strains, including those used in all approved vaccine formulations. Individuals receiving two doses of mRNA vaccine BNT162b2 experienced a dramatic loss in neutralization titers against the Omicron variant[1]. While current protection studies have focused on antibody responses as the key effector mechanism that limits infection, CD8 T cells are likely to play critical roles in the prevention of severe disease[2–6]. Indeed, there are case reports of patients with impaired humoral immunity where efficient T cell responses appear sufficient for viral clearance[7,8].

In response to the changing landscape of viral evolution and spread, vaccine recommendations have been continually updated to include a booster dose, representing a third immunization at least six months after the initial dose of the Pfizer/BioNTech or Moderna mRNA vaccines. Despite these measures, significant numbers of so-called "breakthrough" COVID-19 cases are being recorded, with individuals becoming infected after two or three vaccine doses or even after prior infection. In all of these settings, adaptive immunity is repeatedly exposed to SARS-CoV-2 antigens, and the effects of this recurrent boosting on the functional profile, magnitude, and specificity distribution of responding T cells remain poorly understood[9,10]. In particular, it is largely unknown if repeated exposure to the same SARS-CoV-2 antigens boosts pre-existing T cell memory and, further, if an exposure to a novel antigen (e.g, infection after vaccination or infection with a new viral variant) induces *de novo* memory and diversifies the TCR repertoire, or instead preferentially expands previously primed responses.

CD8 T cells recognize antigen presented on the cell surface by the Class I Major Histocompatibility Complex (MHC), which is encoded by the most polymorphic genes in the human population (Human Leukocyte Antigen, HLA genes)[11]. Variability of peptide-MHC across and within donors makes measuring epitope-specific T cell responses challenging, and as a result, studies often rely on bulk response assays (e.g., peptide stimulation). Although peptide stimulation assays in principle can provide an estimate of the total magnitude of the CD8 response, they underestimate the frequency of epitope-specific T cells[12] Further, because these assays require cellular activation to detect a response, they prevent the direct assessment of cell phenotypes *ex vivo*. Staining with MHC-multimers loaded with individual peptides is an alternative approach,

which requires pre-selection of immunogenic peptides. Several SARS-CoV-2 epitopes presented

by common HLA alleles were discovered in the past two years, permitting the tracking of epitope-

specific T cell responses in infected[13–26] and vaccinated individuals[9,12] using MHC-multimers.

Here we utilized DNA-barcoded MHC-dextramers with subsequent scRNAseq and scTCRseq to

investigate the effects of repeated antigen exposures (SARS-CoV-2 infections and vaccinations

with Pfizer/Biontech BNT162b2) on the key features of the CD8 T cell response, including

response magnitude, functional gene expression profiles (assessed directly *ex vivo*), and the

constituent T cell receptor repertoire. In other contexts, persistent exposure to antigen has been

shown to drive various forms of T cell dysfunction, including exhaustion[27]. Further, the focused

priming on SARS-CoV-2 spike antigens, the only component of all approved vaccines, may bias

subsequent responses during a breakthrough infection towards recall to spike. Thus, it is crucial to

understand how pre-existing T cell memory impacts the immune response and memory formation

to novel SARS-CoV-2 antigens after repeated exposures.

Results

Antibody responses to SARS-CoV-2 infection and vaccination

To investigate the effect of repeated SARS-CoV-2 antigen exposure on pre-existing memory T

cells, we selected a cohort of 55 individuals from SJTRC, a prospective, longitudinal study of St.

Jude Children's Research Hospital adult (≥18 years old) employees (Fig. 1a). Sixteen of these

participants remained negative for SARS-CoV-2 during weekly PCR testing (naive, N1-N16),

whereas 30 of the subjects were diagnosed as SARS-CoV-2 positive with a PCR test and recovered

from mild disease (recovered, R1-R30) during the study period. Both the naive and recovered

groups received two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine, and plasma and

PBMC samples were collected for all subjects after the second dose of vaccine and at various

earlier time points. This produced four subgroups with distinct antigen exposure combinations:

infection only (inf, R1-R16), vaccinated only (vax2, N1-N16), infected followed by one dose of

vaccine (inf-vax1, R17-R26), and infected followed by two doses of vaccine (inf-vax2, R1-R26).

All inf and inf-vax1 subjects were also sampled after their second dose of vaccine, and therefore

have matched samples in the inf-vax2 group (Fig. 1b). Additionally, we collected samples from 9

donors who tested positive for SARS-CoV-2 after receiving both doses of BNT162b2 and

experienced symptomatic breakthrough infection (vax2-inf, or "breakthrough" group, B1-B9). As
expected, the only group negative for N-protein specific antibodies was the vax2 group that was
not infected with SARS-CoV-2 (Extended data Fig. 1a). In concordance with previous reports[28–
30], we observed anti-RBD (Fig. 1c, Extended data Fig. 1b) and anti-spike protein IgG (Extended
data Fig. 1c) boost after vaccination of recovered individuals. Also in line with other studies[28–33],
most of the antibody boost in SARS-CoV-2 recovered individuals is caused by the first rather than
the second vaccine dose, as only two donors (R20, R26) showed a boost in anti-RBD antibody
levels after the second vaccine dose, while antibody levels in other donors remained stable
(Extended data Fig. 1b). Overall, anti-RBD (Fig. 1c) and anti-spike IgG levels (Extended data Fig.
1c) were similar between vax2 and inf-vax groups. However, breakthrough cases exhibited
significantly, but not dramatically, lower anti-RBD and anti-spike antibody levels after infection
compared to both vax2 and inf-vax2 individuals (Fig. 1c).

Magnitude of epitope-specific CD8$^+$ T cell response to mRNA infection and vaccination
To evaluate epitope-specific CD8$^+$ T cell responses to SARS-CoV-2 antigen exposure, we
investigated previously published data for spike-derived epitopes with a resolved HLA-restriction
confirmed in multiple publications. This search resulted in the selection of six spike protein
epitopes presented on the HLA alleles A*01:01, A*02:01, A*24:02, B*15:01, and
B*44:02[13,15,17,20,24–26,34–36]. We then added 12 previously described non-spike epitopes presented
on the same HLA molecules, resulting in a total panel of 18 SARS-CoV-2 epitopes (Fig. 1d,
Extended data Table 1). In addition, four of the selected epitopes (A24_VYI, B15_NQK,
B44_AEV and B44_VEN) were highly similar to orthologs from common cold coronaviruses
(CCCoV), and the CCCoV variant pMHC-dextramers were also included to test the cross-reactive
potential of these epitopes[37–40].

PBMCs from each donor were stained with a panel of DNA-barcoded, fluorescently labeled
dextramers (Fig. 1a, Extended data Table 1) that matched the donor's HLA alleles (Extended data
Table 2). For vax2 donors, these panels only included spike-derived dextramers. Epitope-specific
T cells (CD3$^+$CD8$^+$dextramer$^+$ cells) were isolated using FACS (Extended data Fig. 2) and then
assayed with scRNAseq, scTCRseq, and CITEseq using the 10x Chromium platform. We observed
a detectable (>0.01%) dextramer-positive CD8$^+$ T cell response in 15/16 vaccinated donors that

were not previously infected and in 37/39 SARS-CoV-2-infected donors. Although the overall

frequency of dextramer-specific cells was low (0.41±0.17% SEM of $CD8^+$ T cells; range: 0.01-

14.1% of $CD8^+$ T cells), it was comparable to the epitope-specific memory cell frequencies

observed months after challenge in other studies of SARS-CoV-2 infection[13,17,20,21], even though

these studies frequently used peptide stimulation covering an entire protein or multiple proteins.

Furthermore, the absolute magnitude of the epitope-specific T cell responses was similar across

all groups (Fig. 1e) despite varying sources (vaccine/infection) of antigen exposure (p>0.05 for all

pairwise comparisons, Mann-Whitney U test with Benjamini-Hochberg multiple testing

correction).

*HLA-B*15:01 presents a spike-derived epitope cross-reactive to CCCoV*

Use of the DNA-barcoded dextramers allowed us to deconvolve the overall T cell response to 18

distinct epitope-specific responses. For each cell, we calculated the number of unique molecular

identifiers (UMIs) per dextramer, and considered a cell as dextramer-specific if more than 30% of

the dextramer-derived UMIs corresponded to that dextramer's specific barcode. Cells that did not

match the criteria (i.e., exhibited ambiguous binding or fewer than 4 UMIs per most abundant

dextramer) were considered unspecific binders and were excluded from the dataset. This resulted

in non-overlapping dextramer-positive and -negative groups of cells for each dextramer (Fig. 2a,

Extended data Fig. 3). To further assess this threshold, we considered the dextramer assignment

of individual cells among the 43 most abundant T cell clones (i.e., clonotypes with ≥ 20 cells) as

defined by scTCRseq. Of these clonotypes, 72% (31/43) matched a single epitope across all cells

(Fig. 2b), with only six of the most abundant clonotypes assigned to several non-orthologous

epitopes. However, for all these clonotypes, there was a clear dominant epitope assigned to the

majority of cells, demonstrating the general robustness of the dextramer specificity thresholds.

Interestingly, five of the most abundant TCR clonotypes were assigned to both B15-NQK_Q

SARS-CoV-2 and B15-NQK_A CCCoV (HKU1/OC43) orthologs of the spike epitope, supporting

our initial hypothesis for potential SARS-CoV-2/CCCoV epitope cross-reactivity. Indeed, the

UMI counts for the dextramers with SARS-CoV-2 and CCCoV variants of the epitope were

strongly correlated (Fig. 2c), suggesting that the exact same cells can bind both versions of the

epitope.

To further validate that a single TCR could recognize both variants of B15-NQK, we made a Jurkat
cell line expressing one of the potentially cross-reactive αβTCRs. This T cell line recognized both
CCCoV and SARS-CoV-2 variants of the peptide, as demonstrated by HLA-B*15:01-multimer
staining (Fig. 2d) and peptide stimulation assays (Extended data Fig. 4). Interestingly, the presence
of T cells specific to this epitope coincided with higher IgG levels against the spike protein of
common cold betacoronaviruses HKU1 and OC43 prior to infection or vaccination (Extended data
Fig. 5). These data indicate that SARS-CoV-2 may reactivate cross-reactive memory CD8$^+$ T cells
established during previous OC43/HKU1 infections.

Spike vs. non-spike response distribution varies with antigen exposures
Because barcoded dextramers allow us to simultaneously measure the response to multiple
epitopes in the same sample at single-cell resolution, we also utilized these data to compare the
magnitude of the response to different epitopes. Among all the tested epitopes, A01_TTD,
A01_LTD, A02_YLQ, and B15_NQK elicited the strongest overall response (Fig. 2e) and were
also found in the majority of HLA-matched samples. Although we observed responses to all other
epitopes, they occurred at lower frequencies and only in a subset of HLA-matched donors.

Donors with distinct HLA alleles present different subsets of epitopes. Thus, to robustly compare
the magnitude of spike and non-spike responses, we characterized the contribution of each of the
six A*01:01 restricted epitopes in HLA-A*01:01-positive SARS-CoV-2 convalescent individuals
(n=13). Interestingly, the proportion of the spike-derived epitope A01_LTD response significantly
increased in inf-vax2 individuals compared to infected individuals prior to vaccination (0.8%
A01_LTD-specific cells of total A01-restricted response for inf-only group, vs 48% A01_LTD-
specific cells of total A01-restricted response for inf-vax2, p<0.0001 Fisher exact test; Fig. 2f).
Similar but less striking effects were also observed within HLA-A*02:01-positive individuals
(n=19) for three A*02:01 restricted epitopes (33% of A02_YLQ-specific cells for inf-only, vs 82%
of A02_YLQ-specific cells for inf-vax2, p<0.0001 Fisher exact test; Extended data Fig. 6). These
patterns suggest that the distribution of T cell specificities was shifted towards spike-derived
epitopes following vaccination of these previously infected donors (Fig. 2g, Extended data Fig. 7).
Indeed, among all donors regardless of HLA type, we observed a significant increase in the fraction
of the spike-specific T cell response after vaccination, indicating the recall of epitope-specific

memory T cells among previously infected individuals as a result of vaccination (Fig. 2H, p=0.025,

one-sided Wilcoxon signed-rank test). Similar to the antibody response, most of this expansion

was likely due to the first rather than second dose of the vaccine, as we did not observe a T cell

boost between the first and second doses of vaccine in 7/10 subjects (Extended data Fig. 8). In

sum, vaccination is able to potently and selectively expand spike-specific responses.

Given the potent induction and expansion of spike-specific responses by vaccination, even in

individuals who were previously infected, we predicted that infection of previously vaccinated

individuals (breakthrough, vax2-inf) would maintain a spike-specific bias. Surprisingly, we

observed a large non-spike-specific T cell response in the majority of the breakthrough 6/7 (vax2-

inf) cohort (Fig. 2h), indicating that a robust primary response to non-spike SARS-CoV-2 antigens

during the breakthrough infection is not impaired by the presence of spike-specific immune

memory elicited by vaccination. The ratio between spike- and non-spike-specific T cells in

breakthrough cases (vax2-inf) was no different from that of donors who were only infected (inf;

p=0.97, Mann-Whitney U test), indicating that the T cell response to the non-spike antigens is of

comparable magnitude among those who were only infected and and those who experienced

breakthrough infection after vaccination (vax2-inf). Thus, while the magnitude of the epitope-

specific responses is similar across all exposure types, the composition of epitope-specific

responses is clearly skewed by both the number and order of exposures.

Phenotypes of epitope-specific CD8$^+$ T cells following SARS-CoV-2 infection and vaccination

To understand if different types of antigen exposures could also drive divergent phenotypes among

epitope-specific T cells, we leveraged the single-cell gene expression (scGEX) data corresponding

to our TCR and dextramer data. Unsupervised clustering identified 11 distinct transcriptional

subsets of epitope-specific cells (Fig. 3a). These clusters were manually annotated using the

surface abundance of conventional memory markers (CCR7 and CD45RA) measured by CITEseq

(Fig. 3b) and other well-studied expression markers (Fig 3c, Extended data Table 3, Table 4),

allowing us to identify the following populations: Transitional Memory (Effector

memory(EM)/EM with re-expression of CD45RA(EMRA)), EMRA-like, Central Memory

(CM)/T stem cell-like memory (Tscm), Differentiated effectors, naive/Tscm, EM, Resting

effectors, EM with exhaustion markers, Resting memory, CM with *GATA3*, and Cycling. Though

the proportions of these T cell populations varied substantially across antigen exposure contexts,
each gene expression cluster contained cells from all five exposure groups (Fig. 3d, Extended data
Fig. 9, 10, 11). Natural infection, breakthrough cases, and vaccination led to the formation of
potent T cell memory, including highly cytotoxic populations (clusters 0,1,3,5) and populations
with expression of common markers of durable cellular memory (clusters 2,4,8,9), e.g. *TCF7,*
IL7R, and *CCR7* (Fig. 3c).

Repeated exposures cause a shift of T cell memory phenotypes towards EMRA
To determine if a vaccine-induced recall response affects the phenotypes of T cells, we compared
the GEX cluster distribution between inf-only and inf-vax2 donors. We observed a significant
post-vaccination shift towards a more highly differentiated effector phenotype (EMRA, cluster 1)
of spike-specific cells (Fig. 3e, S10, $p<0.0001$, Fisher exact test). Interestingly, there was no such
change for non-spike-specific cells, suggesting that vaccination specifically increased the
proportion of cells in cluster 1 (EMRA-like) among SARS-CoV-2 recovered donors via a recall of
spike-specific memory T cells (Fig. 3f). Indeed, inf-vax1 and inf-vax2 groups were characterized
by spike-specific T cells with higher *GZMB, GZMH, GNLY,* and *NKG7* expression and lower
TCF7, IL7R, SELL, and *LTB* expression than those in other groups, consistent with the EMRA
phenotype (Fig. 3g). Interestingly, the spike-specific T cells in breakthrough infections (vax2-inf)
exhibited expression profiles more similar to groups with a single type of antigen exposure (vax2
or inf) than to those of inf-vax1,2 subjects.

Repeated SARS-CoV-2 antigen exposure does not lead to an exhausted T cell phenotype
Repeated or chronic antigen exposure leads to T cell exhaustion in multiple experimental models[27].
Several publications have linked T cell exhaustion to an impaired SARS-CoV-2 cellular
response[41–43]. While our epitope-specific data similarly included a cluster with high expression of
classical exhaustion markers (cluster 7, EM-Ex, Fig. 3c), including *CTLA-4, PD-1, TOX,* and
TIGIT, this cluster was present in multiple donors (26/51) across all groups, including vax2-only
(Extended data Fig. S9, S10). In concordance with previous reports[23,42], this "exhausted cluster"
was extremely clonal in composition (Extended data Fig. 12), with more than 70% of the cluster
repertoire occupied by just 10 clones (Fig. 3h). We also observed that the number of cells in the
"exhausted cluster" within a patient strongly correlated with the number of cells in the cluster of

cycling cells (Fig. 3i). Thus, the presence of the exhausted cluster is connected to both clonal

expansion and cell proliferation, suggesting that donors who have such cells are still in the active

rather than memory state of the CD8 T cell response. To test this, we looked at the distribution of

cells among clusters at two available time points after infection (Fig. 1b, donors R1-R30, average

time between timepoints was 75.5 days, range 40-126). The number of cells in cluster 7 declined

with time (Extended data Fig. 13), indicating that this "exhausted" subset is both common among

mild infections yet transient and, importantly, that the presence of these cells is not sufficient to

cause notable pathology. Rather, the exhaustion phenotype appears primarily correlated with time

since antigen exposure.

Convergent and diverse TCR repertoire of epitope-specific CD8$^+$ cells

Our data thus far indicate that vaccination after infection boosts pre-existing T cell memory to

spike antigens and leads to significant alterations in the cellular phenotypes. We next asked

whether this recall response affects the diversity of the underlying recruited T cell receptor

repertoires, potentially narrowing repertoire diversity after each exposure. To compare the TCR

repertoires of epitope-specific cells elicited in response to different exposure contexts, we assessed

the overall TCRβ repertoire diversity (represented by normalised Shannon entropy). The diversity

of both spike- (Fig. 3j) and non-spike-specific repertoires (Fig. 3k) was comparable among all

groups (p=0.63 for spike, p=0.17 for non-spike, Kruskal-Wallis H test), suggesting that a diverse

repertoire of T cells persists in the memory compartment regardless of antigenic history and is not

narrowed by the recall response. This is especially notable among the breakthrough infections, as

it indicates that these individuals mount *de novo* diverse non-spike-specific T cell memory in

response to the infection.

We and others have previously shown that T cells recognizing the same epitopes frequently have

highly similar T cell receptor sequences[44–46]. We therefore constructed a similarity network of

paired, unique αβTCR sequences from our data (Extended data, Table 5), using a threshold on the

TCRdist[44] similarity measure to identify highly similar clonotypes (Fig. 4a). The clusters of similar

sequences almost exclusively consisted of TCRs with the same epitope specificity and feature

biases in V-segment usage (Extended data Fig. 14, 15, 16), as well as striking positional

enrichment of certain amino acid residues within the CDR3 region (Fig. 4b). We next individually

cloned 12 of these TCRs from the 7 largest similarity clusters into a TCR-null Jurkat cell line
(Extended data, Table 6). The resulting cell lines exhibited the expected specificity based on
dextramer barcodes both in peptide stimulation assays (Extended data Fig. 17) and dextramer
staining (Extended data Fig. 18), validating both the bioinformatics approach and the reagents. We
next asked if the same motifs were recruited into the response across antigen exposure histories.
Importantly, many of the confirmed CDR3 motifs from spike-specific TCRs were shared among
donors who recovered from natural infection, including breakthrough infections, and among
immunologically naive donors after vaccination (Fig. 4c). This suggests that epitope recognition
is achieved by the same TCR-pMHC molecular interactions regardless of the method of antigen
exposure, and thus one could expect similar specificity to potential epitope variants for memory T
cells elicited by vaccination or natural infection.
309
TCR motifs recognize most mutated epitopes in SARS-CoV-2 variants
Our TCR analyses established that regardless of antigen history, the same dominant TCR motifs
were utilized by subjects responding to a number of important SARS-CoV-2 epitopes. Thus, these
TCRs can be used to probe how memory responses from these exposures will detect epitopes in
variant SARS-CoV-2 strains. To investigate the potential impact of SARS-CoV-2 variants on T
cell recognition, we searched the GISAID for mutations in the selected CD8 epitopes. Mutations
in both current and previous viral lineages were included in the analysis if they appeared in at least
10% of a Pango lineage and in at least ten thousand isolates. Notably, no mutations in the studied
epitopes were observed in the Omicron variant. However, we identified 10 mutations among the
200 Pango lineages, including Delta and Gamma WHO variants of concern. Models predicting
peptide-MHC binding (NetMHCpan4.1b[47]) suggest that these mutations do not impact the binding
of the epitope to the restricting HLA allele, as both mutated and wild-type epitope variants are
predicted to be strong binders (Extended data Table 7). Thus, we decided to test whether our
transgenic TCR lines were capable of recognizing these mutated epitopes. All three mutated
epitopes of A01_TTD could be recognized by at least one of our A01_TTD-specific T cell lines.
(Extended data, Fig. 19). Interestingly, one of the mutated A01_TTD epitopes (TT*N*PSFLGRY)
was recognized by one of the two generated TCR lines, highlighting the importance of TCR
diversity in the cross-reactivity to novel variants. Neither A02_YLQ-specific TCR line was
activated by the mutant S:P272L epitope YLQPRTFLL (Extended data, Fig. 19), confirming the

data from Dolton et al. This mutation was speculated to play a role in a second Europe COVID-19

wave in summer-autumn of 2020[48]. However, none of the currently abundant SARS-CoV-2

variants bear this or any other variant of the A02_YLQ epitope at large frequency. Of the four

mutations observed in the A24_NYN epitope, two escaped recognition by both cloned TCR lines

(Extended data, Fig. 19). The mutation L452R affecting A24_NYN is of particular interest as it is

present in over 95% of all Delta variant sequences in GISAID. Whether individuals infected by

the Delta variant could utilize other TCR motifs to recognise this mutated epitope requires further

investigation. Together, our data suggest that the T cell memory repertoire established by SARS-

CoV-2 infection or vaccination has great cross-reactivity potential against novel viral variants, and

further shows that not all of the viral mutations affecting T cell epitopes result in the T cell immune

escape, even from the most public TCR clones.

Discussion

Understanding the effects of multiple antigen exposures, in various contexts, on the development

of effective CD8$^+$ T cell memory against SARS-CoV-2 is important for determining susceptibility

to subsequent infections and the potential for booster vaccination to improve outcomes. To address

this, we analyzed multiple parameters of the CD8$^+$ T cell response across five types of antigen

exposure history and found that repeated antigen exposures (up to three) continued to induce

expansion to the included antigens and drive further functional maturation. Despite this, the

underlying TCR repertoire structure within epitope specific responses maintained diversity, which

is a promising indication of continued vaccine efficacy. Narrowing of TCR diversity has been

shown in a number of contexts to correlate with poor immunological control. As fourth boosters

and increased rates of breakthrough infections are providing additional exposures, these data are a

useful benchmark for determining how these relatively rapid repeat exposures will continue to

mature the response. Close monitoring of these important parameters—magnitude, functional

profile, and repertoire diversity—should be continued in longitudinal cohorts with diverse antigen

exposures.

Breakthrough infections of vaccinated individuals have a much lower risk of causing severe

disease but are a concern for maintaining transmission and exposing vulnerable populations.

Furthermore, breakthrough infections have increased with greater serological drift in emerging

variants of concern, including Delta and Omicron. We found that functional profiles among

breakthrough infections (vax2-inf) were distinct from other forms of antigen exposure but

consistent with effector T cell differentiation and, in fact, demonstrated an arguably earlier

differentiation state than inf-vax2 individuals. In addition, we show that these individuals form

non-spike specific T cell memory at robust levels, indicating that there is not an intrinsic defect

among these individuals in mounting robust anti-SARS-CoV-2 responses and diversifying the T

cell memory pool to SARS-CoV-2 internal proteins. The proportion of breakthrough subject

response targeting spike epitopes was in fact smaller than that of the inf-vax2 subjects, indicating

that individuals with breakthrough infection were not preferentially biased towards spike

responses. This is especially important given the continued emergence of SARS-CoV-2

variants[10,49–51] and the current uprise in breakthrough infection rate.

In the midst of characterizing T cell responses against SARS-CoV-2-specific epitopes, we also

discovered T cells that are cross-reactive for SARS-CoV-2 and common cold coronavirus variants

of an HLA-B*15-restricted immunodominant epitope. The possibility of this cross-reactivity was

hypothesized previously[52], where the clonotypes with this TCR motif were the most expanded in

an HLA-B*15 positive donor. An epitope from N-protein HLA-B*07_SPR has also been shown

to be cross-reactive with HKU1 and OC43 common cold coronaviruses[14,53], although other studies

of T cells specific to these epitopes concluded they were not cross-reactive[5,18]. The extent of

protection in HLA-B*15+ and HLA-B*07+ donors recently infected with common cold

coronaviruses is yet to be determined, but a high frequency of cross-reactive CD8 T cells may

correlate with protection.

The most striking differences we observed based on antigenic history were in the phenotype of

elicited cells. In particular, we found an increase in the fraction of EMRA spike-specific T cells

following vaccination in previously infected subjects (inf-vax2). It remains unclear whether the

EMRA phenotype is associated with more or less durable and efficient protection, and longer

follow-up studies of the durability of memory in vax2-only, inf-only, and inf-vax2 groups should

closely monitor the phenotype of antigen-specific T cell responses and their persistence. This is

particularly relevant given the current routine practice of third, and soon possibly fourth, vaccine

doses.

Precise measurement of epitope-specific T cell and B cell responses is crucial for defining the

correlates of SARS-CoV-2 protection, which will inform vaccination strategies to prevent

pandemic recurrence as additional SARS-CoV-2 variants emerge. The striking similarity between

the magnitude and constituent repertoires of epitope-specific CD8 T cell responses following

infection, vaccination, or infection followed by vaccination, indicate that mRNA vaccines are

capable of inducing nearly equivalent memory as an infection episode and further expanding

previously established responses. These data further suggest that booster shots, if needed to address

antibody-escape to Omicron and other variants, will not substantially alter the repertoires of

established anti-spike T cell memory.

Our data have also provided a useful confirmation of the specific sequence features of several

SARS-CoV-2 epitope-specific responses. The generation of monoclonal T cell lines that can be

used to rapidly survey variant peptides provides an analogous tool as a monoclonal antibody for

characterizing antibody escape mutations. Here, we were able to show subtle variations in the loss

of recognition by multiple TCR lines recognizing the same epitope. These tools can be used to

screen emerging variants of concern and also predict mutations that might lead to relevant epitope

escape.

Our study has several limitations that should be considered. First, we focus on comparisons

between T cells specific for a pre-selected set of CD8[+] epitopes previously identified in large

epitope discovery studies[54]. This set of epitopes, although considerable in size given the nature of

our experiments, does not necessarily cover all immunodominant responses, and may also exclude

novel epitopes induced only by vaccination (though to date none have been reported). Furthermore,

the epitopes chosen are presented on a limited subset of HLA-alleles that, while abundant in

populations of European ancestry, are less representative of other populations. Additional epitope

discovery studies of SARS-CoV-2 and other clinically relevant pathogens covering more HLA

alleles from cohorts of diverse ancestry are important to overcome current biases in the literature

and integral for fully elucidating the complex interactions between genotype, phenotype, and

environment on the immune response. Secondly, we were only able to analyze a relatively small
number of breakthrough infection cases. Our data suggest that, going forward, it will be important
to more exhaustively profile the epitope-specific responses of individuals who experience
breakthrough infections, particularly by obtaining prospective samples after vaccination but prior
to infection.

In addition, we only had access to PBMC samples, which do not allow study of the distinct
features of the cellular response at the site of infection. Particularly in breakthrough infections, if
differential trafficking of memory cells to the airways occurred, it may bias our interpretation of
the observed response. Lastly, the variation in our sampling times across all subgroups may
introduce additional noise due to active T cell response dynamics. More regular and frequent
sampling in a larger cohort of fully vaccinated individuals will facilitate a more exhaustive
understanding of the correlates of protection from SARS-CoV-2 infection and the mechanisms
underlying breakthrough infection.

Online methods

Human cohort

The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study (SJTRC, NCT04362995) is a prospective, longitudinal cohort study of St. Jude Children's Research Hospital adult (≥18 years old) employees. The St. Jude Institutional Review Board approved the study. Participants provided written informed consent prior to enrollment and completed regular questionnaires about demographics, medical history, treatment, and symptoms if positively diagnosed with SARS-CoV-2 by PCR. Study data are collected and managed using REDCap electronic data capture tools hosted at St. Jude[55,56]. Participants were screened for SARS-CoV-2 infection by PCR weekly when on the St. Jude campus. For this study, we selected a cohort of 55 individuals, 16 of which had never tested positive for SARS-CoV-2 (N1-N16), and 39 of which were diagnosed as SARS-CoV-2 positive with a PCR test and recovered from mild disease (R1-R30, breakthrough B1-B9) during the study period. All individuals in this study received two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine. Vaccination data, including vaccine type and date administered, were obtained from the institutional database which required direct confirmation of vaccine administration records before data entry. Previously infected and naive vaccinated individuals (inf-vax2 and vax2) were sampled at similar time points after their vaccine regimen was complete (R1-R30: 45.5±2.8 SEM, range 25-81 days; N1-N16: 40.7±2.7 SEM, range 23-60 days). Finally, the individuals chosen for each group were of similar ages (R1-R30: 44.2±2.5 SEM, range 23-68 years; N1-N16: 44.1±3 SEM, range 29-73 years; B1-B9: 40.1±4.2 SEM, range 24-60 years). For this study, we utilized the convalescent blood draw for SARS-CoV-2 infected individuals (3-8 weeks post-diagnosis) and the post-vaccination samples (3-8 weeks after completion of the vaccine series). For breakthrough infections, we used the convalescent blood draw. An infection was considered a "breakthrough" if an individual tested positive for SARS-CoV-2 infection by PCR after receiving two doses of the Pfizer-BioNTech BNT162b2 vaccine. Blood samples were collected in 8 mL CPT tubes and separated within 24 hours of collection into cellular and plasma components then aliquoted and frozen for future analysis. Human cohort metadata can be found in Extended data Table 2.

HLA typing

High quality DNA was extracted from whole blood aliquots from each participant using the Zymo Quick-DNA 96 Plus Kit (Qiagen). DNA was quantified on the Nanodrop (Thermo Scientific). HLA typing of each participant was performed using the AllType NGS 11-Loci Amplification Kit (One Lambda; Lot 013) according to manufacturer's instructions. Briefly, 50 ng DNA was amplified using AllType NGS 11-Loci amplification primers. The amplified product was then cleaned and quantified on the Qubit 4.0 (Invitrogen). Library preparation of purified amplicons was carried out as described in the protocol, and the AllType NGS Index Flex Kit (Lot 011) was used for barcoding and secondary amplification. Purified, barcoded libraries were quantified using the Qubit DNA HS kit (Invitrogen) and pooled according to the One Lambda Library Pooling table. Pools of up to 48 libraries were then purified and quantified on the TapeStation D5000 (Agilent) before sequencing on a full MiSeq lane at 150x150bp following manufacturer's sequencing specifications. HLA types were called using the TypeStream Visual Software from One Lambda. HLA typing results can be found in Extended data Table 2.

Dextramer generation and cell staining

Peptides with >95% purity were ordered from Genscript and diluted in DMSO to 1 mM. pMHC monomers (500 nM) were generated with easYmer HLA class I (A*01:01, A*02:01, A*24:02, B*15:01, B*44:02) kits (Immunaware) according to the manufacturer's protocol. To generate DNA-barcoded MHC-dextramers we used Klickmer technology (dCODE Klickmer, Immudex). 16.2 µL of HLA monomer (500 nM) were mixed with 2 µL barcoded dCODE-PE-dextramer to achieve an average occupancy of 15 and incubated for at least 1 hour on ice prior to use. Individual dextramer cocktails were prepared immediately before staining. Each cocktail had 1.5 µL of each HLA-compatible barcoded MHC-dextramer-PE and 0.15 µL 100 µM biotin per dextramer pre-mixed to block free binding sites. Samples were divided into 3 batches, and timepoints from the same donor were always processed simultaneously. Donor PBMCs were thawed and resuspended in 50 µL FACS buffer (PBS, 0.5% BSA, 2 mM EDTA). Cells were stained with 5 µL Fc-block (Human TruStain FcX, Biolegend 422302) and a cocktail of dextramers for 15 minutes on ice. After this a cocktail of fluorescently-labeled surface antibodies (2 µL of each: Ghost Dye Violet 510 Viability Dye, Tonbo Biosciences 13-0870-T100; anti-human CD3 FITC-conjugated (Biolegend 300406, clone UCHT1), anti-human CD8 BV711-conjugated (Biolegend, 344734,

clone SK1)) and TotalSeq-C antibodies (1 µL anti-human CCR7 (Biolegend 353251), 1 µL anti-

human CD45RA (Biolegend 304163)) and 2 µL of TotalSeq-C anti-human Hashtag antibodies 1-

10 (Biolegend 394661, 394663, 394665, 394667, 394669, 394671, 394673, 394675, 394677,

394679) were added. Samples were incubated for 30 minutes on ice. Single, Live, CD3-positive,

CD8-positive, dextramer-positive cells were sorted into RPMI (Gibco) containing 10% FBS and

1% penicillin/streptomycin using a Sony SY3200 cell sorter. Sorted cells were immediately loaded

into a 10x reaction. Chromium Next GEM Single-Cell 5' kits version 2 (10x Genomics PN:

1000265, 1000286, 1000250, 1000215, 1000252 1000190, 1000080) were used to generate GEX,

VDJ and Cite-Seq libraries according to the manufacturer's protocol. Libraries were sequenced on

Illumina NovaSeq at 26x90bp read length.

Single-cell RNAseq data analysis

Raw data was processed with Cell Ranger version 6.0.0 (10X Genomics). Three batches were

subsequently combined using the aggregate function with default parameters. Resulting GEX

matrices were analysed with the Seurat R package version 4.0.4 [57]. Following standard quality

control filtering, we discarded low quality cells (nFeatures <200 or >5000, MT% >5%) and

eliminated the effects of cell cycle heterogeneity using the CellCycleScoring and ScaleData

functions. Next, we identified 2,000 variable gene features. Importantly, we excluded TCR/Ig

genes from variable features, so that the gene expression clustering would be unaffected by T cell

clonotype distributions. Next, we removed all non-CD8 cells from the data as well as cells labeled

with antibody hashtag #1 (Biolegend 394661) in batch 3, which were used solely as carrier cells

for the 10X reaction. Clusters were defined with the resolution parameter set to 0.5. Differentially

expressed genes between clusters were identified using the Seurat FindAllMarkers function with

default parameters. Differentially expressed genes for 11 resulting clusters can be found in

Extended data Table 3. R scripts for the final Seurat object generation can be found on GitHub

(https://github.com/pogorely/COVID_vax_CD8).

Donor and epitope assignment using feature barcodes

Cells were processed in 6 batches with each batch making a separate 10X Chromium reaction. In

each batch, individual PBMC samples were uniquely labeled with a combination of DNA-

barcoded hashing antibody (TotalSeq-C anti-human Hashtag antibodies 1-10, Biolegend) and a set

of DNA-barcoded MHC-multimers. We attributed a cell to a certain hashtag if more than 50% of

UMIs derived from hashing antibodies matched that hashtag. Cells specific to certain dextramers

were called similarly: we required more than 30% of dextramer-derived UMIs to contain a

dextramer-specific barcode, and if multiple dextramers passed this threshold the cell was

considered specific to both. If the most abundant dextramer barcode per cell was ≤ 3 UMIs, we

did not assign any epitope specificity to it. Cells were assigned to donors using a combination of

hashing antibody and dextramer barcode. TCRα and TCRβ sequences were assembled from

aggregated VDJ-enriched libraries using the CellRanger (v. 6.0.0) vdj pipeline. For each cell we

assigned the TCRβ and TCRα chain with the largest UMI count. The R script performing feature

barcode   deconvolution,   GEX   and   TCR   join   is   available   on   Github

(https://github.com/pogorely/COVID_vax_CD8) as well as the resulting Extended data Table 4.

TCR repertoire analysis

T cell clones were defined as groups of cells from the same donor with identical nucleotide

sequences of both CDR3α and CDR3β (see Extended data Table 5 for unique T cell clones). To

correct erroneous or missing dextramer assignments for individual cells within a clone we assign

each T cell a specificity of the majority of cells from this clone. To measure the distance between

TCR α/β clonotypes and plot logos for dominant motifs we used the TCRdist algorithm

implementation and plotting functions from *conga* python package[58]. Sequence similarity network

analysis and visualizations were performed with the *igraph* R package[59] and *gephi* software[60]. We

exclude top 1% of vertices and edges with largest betweenness centrality values (which are likely

to occur due to cell doublets or artifacts of scTCR sequencing) to filter out a small number of

spurious connections between motif clusters A TCR motif cluster is then defined as a connected

component on a similarity network. TCRβ repertoire diversity calculation was performed using

normalized Shannon entropy $-(\sum_{i=1}^{n} p_i log_2(p_i))/log_2(n)$, where n is a total number of unique

TCRβ clonotypes, and *pi* is a frequency of *i-th* TCRβ clonotype (defined as the fraction of cells

with this TCRβ amongst all cells in a sample with defined TCRβ).

Artificial antigen-presenting cells (aAPCs)

A gBlock gene fragment encoding full-length HLA-A*01:01, HLA-A*02:01, HLA*A24:02 and

HLA-B*15:01 was synthesized by Genscript and cloned into the pLVX-EF1α-IRES-Puro

lentiviral expression vector (Clontech). Lentivirus was generated by transfecting HEK 293T cells

(American Type Culture Collection (ATCC) CRL-3216) with the pLVX lentiviral vector

containing the HLA insert, psPAX2 packaging plasmid (Addgene plasmid #12260), and pMD2.G

envelope plasmid (Addgene plasmid #12259). Viral supernatant was harvested and filtered

through a 0.45 µm SFCA syringe filter (Thermo Fisher) 24- and 48-hours post-transfection, then

concentrated using Lenti-X Concentrator (Clontech). K562 cells (ATCC CCL-243) were

transduced, then antibiotic selected for one week using 2 µg/mL puromycin in Iscove's Modified

Dulbecco's Medium (IMDM; Gibco) containing 10% FBS and 1% penicillin/streptomycin.

Surface expression of HLA was confirmed via flow cytometry using antibodies against HLA-A,

B, C (PE-conjugated, Biolegend 311406, clone W6/32).

TCR-expressing Jurkat 76.7 cells

TCR chains matching both the biggest clusters of Fig 4B, as well as the B15_NQK-specific

prediction from[52], were selected for Jurkat cell line generation (Extended data Table 6). TCRα and

TCRβ chains for the selected epitope-specific TCRs were modified to use murine constant regions

(murine TRAC*01 and murine TRBC2*01). A gBlock gene fragment was synthesized by

Genscript to encode the modified TCRα chain, the modified TCRβ chain, and mCherry, with all

three genes linked together by 2A sites. This sequence was cloned into the pLVX-EF1α-IRES-

Puro lentiviral expression vector (Clontech). Lentivirus was generated by transfecting HEK 293T

cells (ATCC CRL-3216) with the pLVX lentiviral vector containing the TCR-mCherry insert,

psPAX2 packaging plasmid (Addgene plasmid #12260), and the pMD2.G envelope plasmid

(Addgene plasmid #12259). Viral supernatant was harvested and filtered through a 0.45 µm SFCA

syringe filter (Thermo Fisher) 24- and 48-hours post-transfection, then concentrated using Lenti-

X Concentrator (Clontech). Jurkat 76.7 cells (a gift from Wouter Scheper; variant of TCR-null

Jurkat 76.7 cells that expresses human CD8 and an NFAT-GFP reporter) were transduced, then

antibiotic selected for 1 week using 1 µg/mL puromycin in RPMI (Gibco) containing 10% FBS

and 1% penicillin/streptomycin. Transduction was confirmed by expression of mCherry, and

surface TCR expression was confirmed via flow cytometry using antibodies against mouse TCRβ

constant region (PE-conjugated, Biolegend 109208, clone H57-597) and human CD3 (Brilliant

Violet 785-conjugated, Biolegend 344842, clone SK7).

Intracellular cytokine staining functional assay

Jurkat 76.7 cells expressing the B15_NQK-specific TCR (2.5×10^5) were co-cultured with HLA-B*15:01 aAPCs (2.5×10^5) pulsed with 1 µM of either NQKLIANAF peptide from HKU1/OC43 common cold coronaviruses or NQKLIANQF peptide from SARS-CoV-2, 1 µg/mL each of anti-human CD28 (BD Biosciences 555725) and CD49d (BD Biosciences 555501), brefeldin A (GolgiPlug, 1 µL/mL; BD Biosciences 555029), and monensin (GolgiStop, 0.67 µL/mL; BD Biosciences 554724). An unstimulated (CD28, CD49d, brefeldin A, monensin) and positive control (brefeldin A, monensin, 1X Cell Stimulation Cocktail, PMA/ionomycin; eBioscience 00-4970-93) were included in each assay. Cells were incubated for 6 hours (37 °C, 5% CO_{-2}), washed twice with FACS buffer (PBS, 2% FBS, 1 mM EDTA), then blocked using human Fc-block (BD Biosciences 564220) for 10 minutes at room temperature. The blocked cells were then stained with 1 µL Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-T100) and a cocktail of surface antibodies 1 µL each of anti-human CD8 (Brilliant Violet 785-conjugated, Biolegend 344740, clone SK1), anti-human CD3 (Brilliant Violet 421-conjugated, Biolegend 344834, clone SK7), and anti-mouse TCRβ chain (PE-conjugated, Biolegend 109208) or APC/Fire750-conjugated, Biolegend 109246), clone H57-597) for 20 minutes at room temperature. Surface-stained cells were washed twice with FACS buffer, then fixed and permeabilized using the Cytofix/Cytoperm Fixation/Permeabilization kit (BD Biosciences) according to the manufacturer's instructions. Following fixation and permeabilization, cells were washed twice with 1X Perm/Wash buffer and then stained with a cocktail of intracellular antibodies including 1.25 µL of anti-human IFNγ (Alexa Fluor 647-conjugated, Biolegend 502516, clone 4S.B3) and 1 µL anti-human CD69 (PerCP-eFluor710-conjugated, eBioscience 46-0699-42, clone FN50) at 4 °C for 30 minutes. Cells were washed twice with 1X Perm/Wash buffer, and then were analyzed by flow cytometry on a custom-configured BD Fortessa using FACSDiva software (Becton Dickinson). Flow cytometry data were analyzed using FlowJo v. 10.7.1 software (TreeStar). Responsiveness to peptide stimulation was determined by measuring frequency of NFAT-GFP, IFNγ, and CD69 expression.

Specificity validation of generated Jurkat cell lines

Jurkat 76.7 cells expressing the epitope-specific TCRs (1.5×10^5) were co-cultured with aAPCs (1.5×10^5) expressing the corresponding restricting HLA allele, and pulsed with 1 µM of cognate

SARS-CoV-2 peptide, 1 µg/mL each of anti-human CD28 (BD Biosciences 555725) and CD49d

(BD Biosciences 555501). An unstimulated (CD28, CD49d) and positive control (1X Cell

Stimulation Cocktail, PMA/ionomycin; eBioscience 00-4970-93) were included for each Jurkat

76.7 cell line. Cells were incubated for 8 hours (37 °C, 5% CO_2) then washed with FACS buffer

(PBS, 2% FBS, 1 mM EDTA), resuspended in 50µL FACS buffer, and blocked using human Fc-

block (BD Biosciences 564220) for 10 minutes at room temperature. Cells were then stained with

1 µL Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-T100) and a cocktail of

surface antibodies including 1 µL each of anti-human CD3 (Brilliant Violet 421-conjugated,

Biolegend 344834, clone SK7), 1 µL anti-human CD69 (PerCP-eFluor710-conjugated,

eBioscience 46-0699-42, clone FN50), and anti-mouse TCRβ chain (APC/Fire750-conjugated

(Biolegend 109246), clone H57-597). Cells were incubated for 20 minutes at room temperature

and then washed with FACS buffer. Cells were analyzed by flow cytometry on a custom-

configured BD Fortessa using FACSDiva software (Becton Dickinson). Flow cytometry data were

analyzed using FlowJo software version 10.7.1 (TreeStar). Responsiveness to peptide stimulation

was determined by measuring frequency of NFAT-GFP and CD69 expression.

To further test the specificity of generated Jurkat T cell lines we used dextramer staining with the

same dextramer reagents used for staining PBMCs (above). Jurkat cells were washed with FACS

buffer and resuspended in 50 µL. Cells were blocked with using human Fc-block (BD Biosciences

564220) and then stained with 1 µL of corresponding dextramer and 1 µL Ghost Dye Violet 510

Viability Dye (Tonbo Biosciences 13-0870-T100). A control Jurkat Cell line with known

irrelevant specificity was used as a negative control and was stained with all dextramer reagents

tested. All cells were stained for 40 minutes on ice. After the incubation cells were washed once

with FACS buffer. Cells were analyzed by flow cytometry on a custom-configured BD Fortessa

using FACSDiva software (Becton Dickinson). Flow cytometry data were analyzed using FlowJo

software version 10.7.1 (TreeStar).

Tetramer generation and staining of cross-reactive Jurkat Cell line

Biotinylated HLA-B*15-monomers loaded with NQKLIANQF (SARS-CoV-2) and

NQKLIANAF (CCCoV) versions of the peptide were tetramerised using TotalSeq-C-0951-PE-

Streptavidin (Biolegend 405261, 0.5 mg/mL) and TotalSeq-C-0956-APC-Streptavidin (Biolegend

405283, 0.5 mg/mL). 60 µL of HLA-monomers (500 nM) were mixed with 1 µL of PE-conjugated

(B15_NQKLIANQF) or APC-conjugated (B15_NQKLIANAF) streptavidin reagents and

incubated for 1 hour in the dark on ice. Jurkat 76.7 cells expressing the potentially cross-reactive

TCR were stained with 1 µL Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-

T100) and 5 µL of each MHC-tetramer for 30 minutes on ice. Flow cytometry data were analyzed

using FlowJo software (TreeStar). Cross-reactivity of the Jurkat 76.7 T cell line was determined

by co-staining of the live cells with PE and APC-labeled MHC-tetramers.

Recombinant SARS-CoV-2 proteins and ELISA

Expression plasmids for the nucleocapsid (N) protein, spike protein, and the spike receptor binding

domain (RBD) from the Wuhan-Hu-1 isolate were obtained from Florian Krammer (Icahn School

of Medicine at Mount Sinai). Proteins were transfected into Expi293F cells using a ExpiFectamine

293 transfection kit (Thermo Fisher Scientific) as previously described[61]. Supernatants from

transfected cells were harvested and purified with a Ni-NTA column.

For hCoV and SARS-CoV-2 antibody detection, 384-well microtiter plates were coated overnight

at 4 °C, with recombinant proteins diluted in PBS. Optimal concentrations for each protein and

isotype were empirically determined to optimize sensitivity and specificity. SARS-CoV-2 spike

RBD was coated at 2 µg/mL in PBS. Full-length spike was coated at 2 µg/mL for IgG. N protein

was coated at 1 µg/mL. The spike proteins of hCoV-229E (Sino Biological, 40605-V08B), hCoV-

NL63 (Sino Biological, 40604-V08B), hCoV-HKU1 (Sino Biological, 40606-V08B), or hCoV-

OC43 (Sino Biological, 40607-V08B) were coated at 1 µg/mL for IgG detection. For all ELISAs,

plates were washed the next day three times with 0.1% PBS-T (0.1% Tween-20) and blocked with

3% Omniblok[TM] non-fat milk (AmericanBio; AB10109-01000) in PBS-T for one hour. Plates were

then washed and incubated with plasma samples diluted 1:50 in 1% milk in PBS-T for 90 minutes

at room temperature. Prior to dilution, plasma samples were incubated at 56 °C for 15 minutes.

ELISA plates were washed and incubated for 30 minutes at room temperature with anti-human

secondary antibodies diluted in 1% milk in PBS-T: anti-IgG (1:10,000; Invitrogen, A18805). The

plates were washed and incubated at room temperature with OPD (Sigma-Alrich, P8287) for 10

minutes (for hCoV ELISAs) or SIGMAFAST OPD (Sigma-Alrich; P9187) for 8 minutes (for

SARS-CoV-2 ELISAs). The chemiluminescence reaction was stopped by addition of 3N HCl and

absorbances were measured at 490 nm on a microplate reader. The OD of each sample was

normalized to the OD of the same two positive control samples that were run on each plate. The
normalized OD is the percent ratio of the sample OD to the average OD of the positive controls
for the plate. For the SARS-CoV-2 ELISAs, we first screened samples from prior studies that were
collected before 2019 to identify the background level of the assay. Samples were considered
positive if the normalized OD was greater than two times the average of normalized ODs from all
SARS-CoV-2 negative samples in the SJTRC cohort (n=912). For the hCoV ELISAs, we screened
samples from a prior study that included very young children to identify samples to serve as
negative controls. Samples with a normalized OD greater than three times the average of the
normalized ODs for the negative controls were considered positive for the hCoV antigens.
Antibody levels for each donor can be found in the Extended data Table 2.

Analysis of epitope mutations in SARS-CoV-2 variants
We used the WHO definition of variant of concern and variant of interest updated January 10,
2022. A mutation was included in the analysis if it appears in at least 10% of the GISAID
(www.gisaid.org/hcov19-variants/, accessed on Dec 7 2021) isolates with the same Pango lineage
and appears in >1000 isolates from that Pango lineage (Rambaut et al. 2020). To analyze the
predicted binding of variant and wild type peptides, we used NetMHCpan 4.1b[47]. Results of this
analysis are in Extended data Table 7.

Statistical analysis
Statistical analysis was performed in R version 4.0.2. Wilcoxon signed-rank test was used to
compare paired pre-vaccination and post-vaccination samples; only donors with cells collected at
both timepoints were included in the test. Wilcoxon rank-sum test (Mann-Whitney U test) was
used to compare unpaired samples between pairs of study groups, Kruskal-Wallis H test was used
to test for difference between multiple study groups. Multiple testing correction was performed
using the Benjamini-Hochberg procedure. Ns not significant, * $p<0.5$, ** $p<0.01$, *** $p<0.001$

Data and code availability
Code required to reproduce source data for figures is available on GitHub:
https://github.com/pogorely/COVID_vax_CD8. All data produced in the study is available as

supplementary files. Raw sequencing data was deposited to Short Read Archive acc.
PRJNA744851.
715

Acknowledgements

We thank all the donors who volunteered for the SJTRC study, Phil Bradley and Stefan Schattgen for their consultations on TCRdist and conga algorithms, Greig Lennon from St. Jude Immunology flow core for his help with FACS. This work was funded by ALSAC at St. Jude, the Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP) contract number 75N93019C00052 (S.S-C, P.G.T), the St. Jude Center of Excellence for Influenza Research and Surveillance (S.S-C, M.A.M, P.G.T), HHSN272201400006C, 3U01AI144616-02S1 (P.G.T, M.A.M, S.S-C), and R01AI136514 (P.G.T).

Author Contributions

Conceptualization: A.A.M, M.V.P, E.K.A, J.C.C., P.G.T. Formal analysis: A.A.M, M.V.P, A.M.K, J.C.C, M.A.M, J.H.E, X.Z, K.V, G.W. Investigation: A.A.M., M.V.P, A.M.K, C-H.C, R.C.M, M.A.M, J.W, J.E., C-Y.L, D.B, S.T, P.K, D.D. S.M, S.R.O. Methods development: A.A.M, M.V.P, J.C.C., A.M.K, C-Y.L, S.S-C, M.A.M. Resources: S.S-C, M.A.M, P.T, J.H.E., J.W. Data and sample curation: J.W, J.H.E, E.K.A, J.C.C., K.J.A, SJTRC Study Team. Writing, original draft: A.A.M. and M.V.P. Writing, review, and editing: A.A.M, M.V.P, A.M.K, E.K.A, J.C.C, J.W, M.A.M, P.G.T. Visualization: A.A.M., A.M.K. Supervision: P.G.T. Funding Acquisition: P.G.T.

Competing interests

P.G.T has consulted or received honorarium and travel support from Illumina and 10X. P.G.T. serves on the Scientific Advisory Board of Immunoscape and Cytoagents.

Extended data

Extended data Table 1. SARS-CoV-2 derived CD8$^+$ epitopes used for MHC-multimer
generation.

Extended data Table 2. Study participant metadata.

Extended data Table 3. Differentially expressed genes for GEX clusters of epitope-specific CD8+
T cells.

Extended data Table 4. Epitope-specific CD8$^+$ T cells GEX clusters, TCR and epitope specificity.

Extended data Table 5. Unique epitope-specific CD8$^+$ αβTCR clonotypes.

Extended data Table 6: TCR amino acid sequences used for generation of TCR-expressing Jurkat
cell lines

Extended data Table 7. Mutations in studied epitopes from SARS-CoV-2 variants.

Figure 1. Measuring CD8$^+$ T cell epitope-specific responses after diverse SARS-CoV-2 exposures. a.
Study design. Selected spike and non-spike SARS-CoV-2 T cell epitopes were loaded on recombinant
biotinylated MHC-monomers. Resulting peptide-MHC complexes were polymerized using fluorescently
labeled and DNA-barcoded dextran backbones. Next, we stained PBMC samples with pools of MHC-
multimers, isolated bound cells using FACS, and performed scRNAseq, scTCRseq, and CITEseq using the
10X Genomics platform. **b.** Time of blood sampling for each donor is shown relative to the first dose of
mRNA vaccine. **c. Anti-RBD IgG antibody levels in previously infected individuals increase after**
BNT162b2 vaccination. Anti-RBD IgG levels in the plasma were determined by ELISA. The normalized
OD is the percent ratio of the sample OD to the OD of the positive control for each plate. Plasma was
collected from previously infected donors prior (purple, inf), after 1 vaccine dose (inf-vax1, pink), and after
2 vaccine doses (inf-vax2, blue); SARS-CoV-2 naive donors after the full vaccination (vax2, green), and
donors that were infected after vaccination (breakthrough, vax2-inf, yellow). All comparisons were done
with Mann-Whitney U test, p-values are reported after Benjamini-Hochberg correction. Central line on
violin plots depicts the median. **d. List of SARS-CoV-2 epitopes used in this study and summary**
statistics for resulting epitope-specific response. e. Total frequency of MHC-dextramer-positive cells
is similar in all studied groups (p>0.05 for all pairwise comparisons, Mann-Whitney U test after multiple
test correction). Percentage of MHC-multimer-positive cells from all CD8$^+$ T cells measured by flow
cytometry is shown on a log$_{10}$-scale. Central line on violin plots shows the median.

Figure 2. Magnitude, dynamics, and cross-reactivity of CD8+ epitope-specific responses after diverse SARS-CoV-2 exposures. a. **Antigen specificity of each T cell inferred from dextramer-barcode UMI counts.** Representative distribution of the number of UMIs in cells called dextramer-positive (pink) and dextramer-negative (yellow). **b. T cells within a clone have largely consistent specificity assignments, except T cells that cross-react with common cold coronavirus epitopes (B15_NQK_A/B15_NQK_Q pair).** Each bar shows a fraction of cells of a given clonotype attributed to different dextramers. The 43 most abundant clones (more than 20 cells) are shown. **c. The correlation between the number of UMIs for B15_NQK_Q (SARS-CoV-2) and B15_NQK_A (OC43 and HKU1) dextramers (Spearman ρ=0.8, p<0.001)**. **d. Cross-reactivity between HLA-B*15:01-NQK epitope variants confirmed *in vitro*.** Jurkat cell line expressing αβTCR identified from scTCRseq data binds pMHC multimers loaded with both SARS-CoV-2 and CCCoV variants of the epitope. **e. The magnitude of epitope-specific CD8+ T cell responses.** Each point depicts an estimated frequency of epitope-specific T cells in a sample. Estimated frequency was calculated as a fraction of dextramer-specific T cells in scRNAseq results multiplied by bulk frequency of dextramer-stained CD8+ cells of all CD8+ cells measured by flow cytometry. Central line on boxplot shows the median. Epitopes from spike protein are in bold font. **f. Composition of HLA-A*01-restricted T cell response in HLA-A*01 positive donors.** Increasing proportion of spike-targeting T cells (pink) is observed after vaccination of infected individuals. **g. Boosting of spike-specific epitope fraction after vaccination (donor R6). h. Previously infected individuals have a higher proportion of spike-specific T cells after vaccination than before vaccination** (p=0.025, one-sided Wilcoxon signed-rank test). Spike T cell proportion (shown on a log₁₀-scale) was calculated as a fraction of spike-specific T cells out of all CD8+ epitope-specific T cells of a donor in scRNAseq data. Central line on the violin shows the median.

Figure 3. Phenotypic diversity of epitope-specific CD8$^+$ T cells after diverse SARS-CoV-2 exposures.
a. UMAP (Uniform manifold approximation and projection) of all SARS-CoV-2 epitope-specific CD8 T cells based on gene expression (GEX). Color shows results of graph-based unsupervised clustering performed with the Seurat package. **b. Density plot of CCR7 and CD45RA surface expression (measured by CITE-seq) in GEX clusters. c. Bubble plot of representative differentially expressed genes for each cluster.** Size of the circle shows percentage of cells in a cluster expressing a certain gene, color scale shows gene expression level. **d. Distribution of epitope-specific T cells in gene expression clusters between study groups. e. Proportion of spike-specific T cells is significantly increased in cluster 1 after vaccination of previously infected individuals, compared to the pre-vaccination timepoint (p<0.0001, Fisher exact test). f. Proportion of spike-specific cells in EMRA (cluster 1) across study groups for samples with more than ten spike-specific cells (Kruskal-Wallis H test p=0.028).** Central line on boxplot shows the median. **g. Expression of classical cytotoxic and memory markers across study groups and T cell specificities.** Size of the circle shows percentage of cells in a cluster expressing a certain gene, color scale shows gene expression level. **h. Clone size distribution within GEX clusters.** Fractions of cells from 10 most abundant clonotypes in each cluster are shown with colors, all other clonotypes are shown in grey. **i. Number of cells in cluster 7 (Exhausted) and cluster 10 (Cycling) in samples are strongly correlated (Spearman ρ=0.79, p<0.001).** Shaded area shows 95% confidence interval for linear fit. **j-k. T cell repertoire diversity of spike (j) and non-spike specific repertoires across study groups** (p=0.63 for spike, p=0.17 for non-spike, Kruskal-Wallis H test)**.** Normalized Shannon entropy of TCRβ is plotted for samples with more than 3 unique TCRβ clonotypes. Central line on boxplot shows the median.

Figure 4. Diverse polyclonal repertoires of epitope-specific T cells after diverse SARS-CoV-2 exposures a. SARS-CoV-2 epitope-specific αβTCR amino acid clonotypes feature clusters of highly similar sequences with the same epitope specificity. Each node on a similarity network is a unique paired αβTCR amino acid sequence, and an edge connects αβTCRs with TCRdist less than 110. Each color represents a certain epitope specificity. Only clusters with more than two members are shown. Spike-derived epitopes are in bold font. **b. TCR amino acid sequence motifs of α and β chains (TCRdist logos) for the largest clusters of highly similar TCRs for each epitope (circled with dashed line on a). c. TCRs with the same sequence motifs are found across all study groups in a matching HLA-background.** Occurrence of TCR motifs on the left is shown for all HLA matching samples (rectangles on the plot). Grey rectangles represent samples lacking the TCR motif. The color of the rectangle that has a TCR motif corresponds to the sample group.

Extended data Fig. 1. Antibody levels across study groups. Plasma was tested by ELISA for IgG antibodies specific for (**a**) Nucleocapsid (N), (**b**) the receptor-binding domain (RBD) of the spike, (**c**) whole spike protein of SARS-CoV-2. Normalized ODs are the percent ratio of the sample OD to the OD of the positive control samples for each plate. The black horizontal line on the plots indicates the positivity threshold, which is two times the average of the normalized ODs for all SARS-CoV-2 negative samples in the cohort. P-values for Mann-Whitney U test after Benjamini-Hochberg multiple testing correction are reported. Donors sampled before and after mRNA vaccination are connected with a line. P-values (magenta) for paired samples were calculated with the Wilcoxon signed-rank test.

844
845 **Extended data Fig. 2. a. Gating strategy for sorting of single live CD3$^+$CD8$^+$dextramer$^+$ cells. b.**
846 **Representative flow plots for donors stained with the same dextramer pools, but showing different**
847 **frequencies of single live CD3$^+$CD8$^+$dextramer$^+$ cells.**

Extended data Fig. 3. **Dextramer assignment with feature barcodes**. Each subplot shows distribution of Log_{10} (# UMIs) for dextramers with certain feature barcodes in dextramer-negative (yellow) and dextramer-positive (pink) cells. Dextramer with barcode 35 B44_VEN_M did not have any specific cells.

Extended data Fig. 4. **Peptide stimulation confirms cross-reactivity of B15_NQK αβTCR.** From left to right: unstimulated (negative control), NQKLIANQF (SARS-CoV-2) peptide stimulation, NQKLIANAF (OC43 and HKU1) peptide stimulation, PMA/Ionomycin (positive control). Top row: IFN-γ production by TCR-expressing Jurkats measured by intracellular cytokine staining. Middle row: CD69+ surface expression. Bottom row: NFAT-GFP reporter expression.

Extended data Fig. 5. **Antibody titers for CCCoV spike protein and number of B15_NQK cross-reactive cells in HLA-B*15:01[+] donors.** Plasma collected from donors prior to infection or vaccination was tested by ELISA for IgG antibodies to the spike of **a,** hCoV-OC43 or **b,** hCoV-HKU1. The normalized ODs are the percent ratio of the sample OD to the OD of the positive control sample for each plate. The dashed line is the threshold for positivity, which is three times the average of the normalized OD for the negative control samples. **c,** The number of HLA-B*15:01-restricted epitope T cells after infection or vaccination (log-scale).

Extended data Fig. 6. Composition of HLA-A*02-restricted T cell response in HLA-A*02 positive donors. Increasing proportion of spike-targeting T cells (pink) is observed after vaccination of previously infected individuals.

Extended data Fig. 7. Clonal dynamics of spike- and non-spike-specific T cell response for SARS-CoV-2 infected donors before and after two doses of BNT162b2. Each colored ribbon represents an estimated frequency of spike- (pink) or non-spike- (blue) specific T cells.

Extended data Fig. 8. SARS-CoV-2 infected individuals after the first and second BNT162b2 vaccine

doses (inf-vax1 and inf-vax2) have the same proportion of spike-specific T cells (p=0.9, Wilcoxon

signed-rank test). Spike T cell proportion was calculated as a fraction of spike-specific T cells out of all

$CD8^+$ epitope-specific T cells of a donor in scRNAseq data.

Extended data Fig. 9. GEX cluster distribution for each sample. Each colored bar represents a fraction

of cells in a given GEX cluster.

Extended data Fig. 10. UMAP visualization of cells clustered by similarity of GEX. Each subpanel

shows cells from each study group. Top: cells colored by cluster. Bottom: cells colored by spike and non-

spike specificity.

888
889 **Extended data Fig. 11. UMAP visualization of cells clustered by similarity of GEX**. Each subpanel
890 shows cells specific for each of the tested epitopes.

892 **Extended data Fig. 12. "Exhausted" cluster 7 (circled) is enriched with cells from expanded clones.**
893 The color of each dot shows the size of the T cell clone (Log_{10} of number of cells) for each cell.

Figure S13

894
895 **Extended data Fig. 13. Number of cells in the "exhausted" cluster (cluster 7) declines over time. a.**
896 **UMAP visualization of cells clustered by similarity of GEX for donors sampled twice during the study**
897 **(shapes connected with a line on Fig. 1b)**. Timepoint 1 corresponds to inf (R1-R16), inf-vax (R17-R30);
898 timepoint 2 corresponds to inf-vax2 (R1-R30). **b. Fraction of cells in cluster 7 out of all cells.** Only donors
899 with cells in cluster 7 on timepoint 1 are shown.

900
Extended data Fig. 14. VαJα-usage for selected epitopes. Height of each rectangle corresponds to the
fraction of unique epitope-specific T cell clones expressing a given V- or J-segment in the TCRα. Ribbons
show the frequency of VJ combinations.

904
Extended data Fig. 15. VβJβ-usage for selected epitopes. Height of each rectangle corresponds to the
fraction of unique epitope-specific T cell clones expressing a given V- or J-segment in the TCRβ chain.
Ribbons show the frequency of VJ combinations.

Extended data Fig. 16. Vα-Vβ pairings for selected epitopes. Height of each rectangle corresponds to
the fraction of unique epitope-specific T cell clones expressing a given TRAV or TRBV segment. Ribbons
show frequencies of TRAV-TRBV combinations.

912
Extended data Fig. 17. Peptide stimulation confirms specificity of αβTCR motifs. Top: example of the
gating strategy (B15_specific Jurkat line 1, same as Fig. S4). Left column: unstimulated control. Each row
shows stimulation with a single peptide (middle columns), B15 specific TCRs were stimulated with both
NQKLIAN**Q**F (SARS-CoV-2) peptide and NQKLIANA**F** (OC43 and HKU1) peptide; Right column:
PMA/Ionomycin (positive control). Responsiveness of the Jurkat cell lines was determined using an
endogenous NFAT-GFP reporter.

Extended data Fig. 18. MHC-dextramer staining confirms specificity of αβTCR motifs. Top: example
of the gating strategy (B15_specific Jurkat line 1, same as Fig. S4). Left column: control Jurkat cell line
with other known specificity. Each row shows staining with a single MHC-dextramer.

923
924 **Extended data Fig. 19. Recognition of SARS-CoV-2 mutated epitopes by αβTCR motifs.** Left column:
925 unstimulated control. Each row shows stimulation with a single peptide (middle columns). Responsiveness
926 of the Jurkat cell lines was determined using an endogenous NFAT-GFP reporter.
927
928

References

1. Flemming, A. Omicron, the great escape artist. *Nat Rev Immunol* (2022) doi:10.1038/s41577-022-00676-6.

2. Mallajosyula, V. *et al.* CD8 [+] T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19. *Sci. Immunol.* **6**, (2021).

3. Rydyznski Moderbacher, C. *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell* **183**, 996-1012.e19 (2020).

4. Kundu, R. *et al.* Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nat Commun* **13**, 80 (2022).

5. Peng, Y. *et al.* An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. *Nat Immunol* **23**, 50–61 (2022).

6. Swadling, L. *et al.* Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. *Nature* **601**, 110–117 (2022).

7. Bange, E. M. *et al.* CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. *Nat Med* **27**, 1280–1289 (2021).

8. Soresina, A. *et al.* Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. *Pediatr Allergy Immunol* **31**, 565–569 (2020).

9. Oberhardt, V. *et al.* Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. *Nature* **597**, 268–273 (2021).

10. Reynolds, C. J. *et al.* Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science* **372**, 1418–1423 (2021).

11. Robinson, J. *et al.* IPD-IMGT/HLA Database. *Nucleic Acids Research* gkz950 (2019) doi:10.1093/nar/gkz950.

12. Sahin, U. *et al.* BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. *Nature* (2021) doi:10.1038/s41586-021-03653-6.

13. Ferretti, A. P. *et al.* Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared

Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. *Immunity* **53**, 1095-1107.e3

(2020).

14. Francis, J. M. *et al.* Allelic variation in class I HLA determines CD8+ T cell repertoire shape and

cross-reactive memory responses to SARS-CoV-2. *Sci Immunol* eabk3070 (2021).

15. Gangaev, A. *et al.* Identification and characterization of a SARS-CoV-2 specific CD8+ T cell

response with immunodominant features. *Nat Commun* **12**, 2593 (2021).

16. Habel, J. R. *et al.* Suboptimal SARS-CoV-2−specific CD8[+] T cell response associated with the

prominent HLA-A*02:01 phenotype. *Proc Natl Acad Sci USA* **117**, 24384–24391 (2020).

17. Kared, H. *et al.* SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19

individuals. *Journal of Clinical Investigation* **131**, e145476 (2021).

18. Nguyen, T. H. O. *et al.* CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid

epitope display high naive precursor frequency and TCR promiscuity. *Immunity* **54**, 1066-1082.e5

(2021).

19. Nielsen, S. S. *et al.* SARS-CoV-2 elicits robust adaptive immune responses regardless of disease

severity. *EBioMedicine* **68**, 103410 (2021).

20. Peng, Yanchun *et al.* Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in

UK convalescent individuals following COVID-19. *Nat Immunol* **21**, 1336–1345 (2020).

21. Rha, M.-S. *et al.* PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but

Functional in Patients with COVID-19. *Immunity* **54**, 44-52.e3 (2021).

22. Saini, S. K. *et al.* SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and

substantial CD8[+] T cell activation in COVID-19 patients. *Sci. Immunol.* **6**, eabf7550 (2021).

23. Schreibing, F. *et al. Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell

epitope mapping.* http://biorxiv.org/lookup/doi/10.1101/2021.03.03.432690 (2021)

doi:10.1101/2021.03.03.432690.

24. Schulien, I. *et al.* Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells.

Nat Med **27**, 78–85 (2021).

25. Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild

COVID-19. *Cell* **183**, 158-168.e14 (2020).

26. Shomuradova, A. S. *et al.* SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse

Repertoire of Human T Cell Receptors. *Immunity* **53**, 1245-1257.e5 (2020).

27. Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol*

15, 486–499 (2015).

28. Ebinger, J. E. *et al.* Antibody responses to the BNT162b2 mRNA vaccine in individuals previously

infected with SARS-CoV-2. *Nat Med* **27**, 981–984 (2021).

29. Goel, R. R. *et al.* Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and

recovered individuals following mRNA vaccination. *Sci. Immunol.* **6**, eabi6950 (2021).

30. Krammer, F. *et al.* Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2

mRNA Vaccine. *N Engl J Med* **384**, 1372–1374 (2021).

31. Lozano-Ojalvo, D. *et al.* Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T

cell immunity in naive and COVID-19 recovered individuals. *Cell Reports* **36**, 109570 (2021).

32. Mazzoni, A. *et al.* First-dose mRNA vaccination is sufficient to reactivate immunological memory to

SARS-CoV-2 in subjects who have recovered from COVID-19. *Journal of Clinical Investigation*

131, e149150 (2021).

33. Wang, Z. *et al.* Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after

infection. *Nature* (2021) doi:10.1038/s41586-021-03696-9.

34. Nelde, A. *et al.* SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell

recognition. *Nat Immunol* **22**, 74–85 (2021).

35. Snyder, T. M. *et al. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at*

Both Individual and Population Levels. http://medrxiv.org/lookup/doi/10.1101/2020.07.31.20165647

(2020) doi:10.1101/2020.07.31.20165647.

36. Tarke, A. *et al.* Comprehensive analysis of T cell immunodominance and immunoprevalence of

SARS-CoV-2 epitopes in COVID-19 cases. *Cell Reports Medicine* **2**, 100204 (2021).

37. Braun, J. *et al.* SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature*

587, 270–274 (2020).

38. Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-

19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501.e15 (2020).

39. Le Bert, N. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and

uninfected controls. *Nature* **584**, 457–462 (2020).

40. Mateus, J. *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Science **370**, 89–94 (2020).

41. Diao, B. *et al.* Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease

2019 (COVID-19). *Front. Immunol.* **11**, 827 (2020).

42. Kusnadi, A. *et al.* Severely ill COVID-19 patients display impaired exhaustion features in SARS-

CoV-2-reactive CD8$^+$ T cells. *Sci. Immunol.* **6**, eabe4782 (2021).

43. Zheng, H.-Y. *et al.* Elevated exhaustion levels and reduced functional diversity of T cells in

peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol* **17**, 541–

543 (2020).

44. Dash, P. *et al.* Quantifiable predictive features define epitope-specific T cell receptor repertoires.

Nature **547**, 89–93 (2017).

45. Glanville, J. *et al.* Identifying specificity groups in the T cell receptor repertoire. *Nature* **547**, 94–98

(2017).

46. Thomas, N. *et al.* Tracking global changes induced in the CD4 T-cell receptor repertoire by

immunization with a complex antigen using short stretches of CDR3 protein sequence.

Bioinformatics **30**, 3181–3188 (2014).

47. Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-

4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and

integration of MS MHC eluted ligand data. *Nucleic Acids Research* **48**, W449–W454 (2020).

48. Dolton, G. *et al. Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope.*

http://medrxiv.org/lookup/doi/10.1101/2021.06.21.21259010 (2021)

doi:10.1101/2021.06.21.21259010.

49. Altmann, D. M., Boyton, R. J. & Beale, R. Immunity to SARS-CoV-2 variants of concern. *Science*

371, 1103–1104 (2021).

50. Geers, D. *et al.* SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in

COVID-19 convalescent donors and vaccinees. *Sci. Immunol.* **6**, eabj1750 (2021).

51. Tarke, A. *et al.* Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in

infected or vaccinated individuals. *Cell Rep Med* **2**, 100355 (2021).

52. Minervina, A. A. *et al.* Longitudinal high-throughput TCR repertoire profiling reveals the dynamics

of T-cell memory formation after mild COVID-19 infection. *eLife* **10**, e63502 (2021).

53. Lineburg, K. E. *et al.* CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid

epitope cross-react with selective seasonal coronaviruses. *Immunity* **54**, 1055-1065.e5 (2021).

54. Grifoni, A. *et al.* SARS-CoV-2 Human T cell Epitopes: adaptive immune response against COVID-

19. *Cell Host & Microbe* S1931312821002389 (2021) doi:10.1016/j.chom.2021.05.010.

55. Harris, P. A. *et al.* Research electronic data capture (REDCap)—A metadata-driven methodology and

workflow process for providing translational research informatics support. *Journal of Biomedical*

Informatics **42**, 377–381 (2009).

56. Harris, P. A. *et al.* The REDCap consortium: Building an international community of software

platform partners. *Journal of Biomedical Informatics* **95**, 103208 (2019).

57. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573-3587.e29 (2021).

58. Schattgen, S. A. *et al.* Integrating T cell receptor sequences and transcriptional profiles by clonotype

neighbor graph analysis (CoNGA). *Nat Biotechnol* (2021) doi:10.1038/s41587-021-00989-2.

59. Csardi, G. & Nepusz, T. The igraph software package for complex network research. *InterJournal*

Complex Systems, 1695 (2006).

60. Jacomy, M., Venturini, T., Heymann, S. & Bastian, M. ForceAtlas2, a Continuous Graph Layout

Algorithm for Handy Network Visualization Designed for the Gephi Software. *PLoS ONE* **9**, e98679

(2014).

61. Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* **26**,

1033–1036 (2020).